INT16390

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1986
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 13
Total Number 15
Disease Relevance 6.72
Pain Relevance 3.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plg) extracellular space (Plg) extracellular region (Plg)
Anatomy Link Frequency
blood 1
Platelet 1
Plg (Mus musculus)
Pain Link Frequency Relevance Heat
narcan 7 99.78 Very High Very High Very High
Angina 18 99.48 Very High Very High Very High
opiate 3 98.92 Very High Very High Very High
antagonist 5 98.64 Very High Very High Very High
analgesia 6 98.60 Very High Very High Very High
Somatostatin 1 98.44 Very High Very High Very High
ischemia 5 96.96 Very High Very High Very High
long-term potentiation 2 95.28 Very High Very High Very High
headache 1 79.04 Quite High
Endogenous opioid 2 75.76 Quite High
Disease Link Frequency Relevance Heat
Aggression 8 100.00 Very High Very High Very High
Myocardial Infarction 10 99.92 Very High Very High Very High
Disease 87 99.64 Very High Very High Very High
Cv General 3 Under Development 15 99.48 Very High Very High Very High
Syndrome 5 98.28 Very High Very High Very High
Coronary Artery Disease 4 97.40 Very High Very High Very High
Cancer 11 96.00 Very High Very High Very High
Thrombosis Related Under Development 1 94.08 High High
Thrombosis 5 93.96 High High
Asthma 83 92.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The plasminogen system is negatively controlled by the action of soluble protein inhibitors that selectively bind plasminogen or plasmin.
Regulation (controlled) of plasminogen system
1) Confidence 0.48 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.12 Pain Relevance 0.03
Inhibitory influences of MIF-1 (PLG) and Tyr-MIF-1 (YPLG) on aggression and defeat-induced analgesia in mice.
Regulation (influences) of PLG associated with aggression, narcan and analgesia
2) Confidence 0.44 Published 1986 Journal Peptides Section Title Doc Link 2882493 Disease Relevance 0.18 Pain Relevance 0.61
Inhibitory influences of MIF-1 (PLG) and Tyr-MIF-1 (YPLG) on aggression and defeat-induced analgesia in mice.
Regulation (influences) of PLG associated with aggression, narcan and analgesia
3) Confidence 0.44 Published 1986 Journal Peptides Section Title Doc Link 2882493 Disease Relevance 0.19 Pain Relevance 0.62
The effects on offensive aggression of the endogenous peptide-leucyl-glycinamide (PLG, MIF-1) and the exogenous opiate antagonist, naloxone, were examined in male mice.
Spec (examined) Regulation (effects) of PLG associated with antagonist, aggression, narcan and opiate
4) Confidence 0.27 Published 1986 Journal Life Sci. Section Abstract Doc Link 2877382 Disease Relevance 0.33 Pain Relevance 0.35
Importantly, polymorphisms in the u-PA gene have been proposed to be associated with late-onset AD, suggesting that deregulation of the plasminogen system may be associated with the pathogenesis of the disease [12].
Regulation (deregulation) of plasminogen system associated with disease
5) Confidence 0.24 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.55 Pain Relevance 0.05
Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators.
Regulation (response) of plasminogen in Platelet associated with angina
6) Confidence 0.21 Published 1991 Journal Am. J. Cardiol. Section Title Doc Link 1892067 Disease Relevance 0.81 Pain Relevance 0.56
Recently, targeted angiostatin and endostatin gene transfer [24,25] has been attempted as a means to halt angiogenesis in a mouse tumor model.
Regulation (targeted) of angiostatin associated with cancer
7) Confidence 0.19 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2913137 Disease Relevance 0.66 Pain Relevance 0.08
Finally, it is noteworthy that our unchanged levels of hPGD synthase suggest that PGD2 production was probably unaffected [54], and, therefore, that the impact of this PG on the oligonucleotide-induced changes was limited.
Regulation (limited) of PG
8) Confidence 0.18 Published 2008 Journal Respir Res Section Body Doc Link PMC2600823 Disease Relevance 0.54 Pain Relevance 0.13
No PEDF expression was detected in rAAV-angiostatin-infected HUVEC-2C cells (Figure 7B).
Regulation (detected) of angiostatin
9) Confidence 0.16 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2533034 Disease Relevance 0.29 Pain Relevance 0
How and when these opposing functions occur should be the focus of future research to identify potential pharmacological targets in the COX-2/PG system.


Regulation (targets) of PG
10) Confidence 0.11 Published 2008 Journal Respir Res Section Body Doc Link PMC2600823 Disease Relevance 0.14 Pain Relevance 0
Circulating plasminogen activator inhibitors might regulate fibrinolysis by increasing the clearance of t-PA from the blood.
Spec (might) Regulation (regulate) of plasminogen in blood
11) Confidence 0.02 Published 1993 Journal Dan Med Bull Section Abstract Doc Link 8222763 Disease Relevance 0.07 Pain Relevance 0
The concentrations of pro-u-PA, plasminogen and Spectrozyme UK were as 20 nM, 5 nM and 100 ?
Regulation (concentrations) of plasminogen
12) Confidence 0.02 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0 Pain Relevance 0
With its "clot-selectivity", t-PA is capable of lysing clots without having a significant effect on circulating plasminogen.
Regulation (effect) of plasminogen
13) Confidence 0.02 Published 1987 Journal Pharmacotherapy Section Abstract Doc Link 3120160 Disease Relevance 0.31 Pain Relevance 0
Plasminogen, alpha 2 antiplasmin and fibrinogen values decreased significantly after thrombolytic treatment.
Regulation (values) of Plasminogen
14) Confidence 0.01 Published 1991 Journal Am. J. Cardiol. Section Abstract Doc Link 1827942 Disease Relevance 1.35 Pain Relevance 0.65
In contrast, TXA and EACA are synthetic lysine analogs that bind to and produce a structural change in plasminogen preventing conversion of plasminogen to plasmin and conversion of fibrinogen to fibrin.
Regulation (change) of plasminogen
15) Confidence 0.01 Published 2010 Journal BMC Surg Section Body Doc Link PMC2858129 Disease Relevance 1.17 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox